|
|
|
|
|
Part III: Pharmaceutical and Formulation Factors |
|
|
|
| |
|
|
|
|
|
5. Pharmaceutical Issues in Drug Development |
|
|
|
Umesh V. Banakar and Michael C. Makoid | |
|
|
|
|
|
6. Novel Drug Delivery Systems |
|
|
|
Bret Berner and Agis Kydonieus | |
|
|
|
|
|
Part IV: Drug Design, Pharmacokinetics, and Toxicology |
|
|
|
| |
|
|
|
|
|
7. Computer-Aided Drug Design |
|
|
|
Terry R. Stouch | |
|
|
|
|
|
8. New Approaches to Nonclinical Biodisposition Studies |
|
|
|
D. Bruce Campbell | |
|
|
|
|
|
9. Changes in Pharmacokinetics and Drug Metabolism Responsibility in Drug Discovery and Development |
|
|
|
Peter G. Welling | |
| |
|
|
|
|
|
10. Anticancer Drug Development |
|
|
|
Jim Cassidy | |
|
|
|
|
|
Part VI: Clinical Studies and the Use of Clinical Research Organizations |
|
|
|
| |
|
|
|
|
|
11. Clinical Pharmacology in Drug Development: A View to Future Effectiveness |
|
|
|
J. Robert Powell, Alan Bye, and Paul D. Rubin | |
|
|
|
|
|
12. Contracting CROs into Your Organization: New Strategies for New Challenges |
|
|
|
Gary D. Lightfoot and John R. Vogel | |
|
|
|
|
|
13. The Role of Clinical Research Organizations in Drug Development |
|
|
|
Albert J. Siemens and James E. Higgins | |
|
|
|
|
|
Part VII: European and Japanese Approaches |
|
|
|
| |
|
|
|
|
|
14. Understanding Drug Development and Registration in Japan |
|
|
|
W. J. C. Currie | |